Key Points
- Immunome insider Kinney Horn sold 90,616 shares at an average price of $25.09, generating $2.27 million. The Rule 10b5-1 transaction reduced Horn’s direct ownership by 64.27% to 50,366 shares.
- Immunome shares opened at $25.82, near their one-year high of $27.65, while the company reported a quarterly loss of $0.48 per share—better than the expected $0.60 loss.
- Analyst sentiment remains broadly positive, with 12 Buy ratings and one Sell rating producing a “Moderate Buy” consensus and an average price target of $34.18; institutional investors own 44.58% of the stock.
Immunome, Inc. (NASDAQ:IMNM - Get Free Report) insider Kinney Horn sold 90,616 shares of the stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $25.09, for a total transaction of $2,273,555.44. Following the sale, the insider directly owned 50,366 shares of the company's stock, valued at approximately $1,263,682.94. This trade represents a 64.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Kinney Horn also recently made the following trade(s):
- On Tuesday, July 7th, Kinney Horn sold 1,092 shares of Immunome stock. The stock was sold at an average price of $25.00, for a total transaction of $27,300.00.
Immunome Stock Performance
IMNM stock opened at $25.82 on Friday. The company's fifty day moving average price is $21.43 and its 200-day moving average price is $22.14. Immunome, Inc. has a one year low of $8.66 and a one year high of $27.65. The company has a market capitalization of $2.92 billion, a PE ratio of -10.85 and a beta of 2.08.
Immunome (NASDAQ:IMNM - Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.12. On average, research analysts predict that Immunome, Inc. will post -2.06 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of brokerages have recently weighed in on IMNM. Wedbush restated an "outperform" rating and set a $31.00 price objective on shares of Immunome in a research report on Tuesday, July 21st. Truist Financial lifted their target price on Immunome from $36.00 to $37.00 and gave the stock a "buy" rating in a report on Thursday, May 28th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Immunome in a research report on Friday, July 17th. HC Wainwright reissued a "buy" rating on shares of Immunome in a research note on Thursday, July 9th. Finally, Barclays began coverage on Immunome in a report on Thursday, May 28th. They set an "overweight" rating and a $36.00 price target for the company. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Immunome currently has an average rating of "Moderate Buy" and a consensus price target of $34.18.
View Our Latest Analysis on Immunome
Institutional Investors Weigh In On Immunome
Hedge funds have recently bought and sold shares of the business. KBC Group NV bought a new position in Immunome during the first quarter valued at $60,000. BNP Paribas Financial Markets grew its stake in shares of Immunome by 81.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company's stock worth $60,000 after buying an additional 2,909 shares in the last quarter. Strs Ohio bought a new stake in shares of Immunome in the 4th quarter worth about $64,000. Tower Research Capital LLC TRC increased its holdings in shares of Immunome by 121.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company's stock worth $65,000 after buying an additional 3,802 shares during the last quarter. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Immunome during the 3rd quarter valued at about $76,000. Hedge funds and other institutional investors own 44.58% of the company's stock.
Immunome Company Profile
(
Get Free Report)
Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome's approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.
The company's lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
